Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study.

de Ruijter TC, Smits KM, Aarts MJ, van Hellemond IEG, Van Neste L, de Vries B, Peer PGM, Veeck J, van Engeland M, Tjan-Heijnen VCG.

Diagn Progn Res. 2019 Oct 17;3:20. doi: 10.1186/s41512-019-0065-6. eCollection 2019.

2.

Author Correction: Analysis of DNA methylation in cancer: location revisited.

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, Van Criekinge W, de Meyer T, van Engeland M.

Nat Rev Clin Oncol. 2018 Jul;15(7):467. doi: 10.1038/s41571-018-0028-9.

PMID:
29713045
3.

Analysis of DNA methylation in cancer: location revisited.

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, Van Criekinge W, De Meyer T, van Engeland M.

Nat Rev Clin Oncol. 2018 Jul;15(7):459-466. doi: 10.1038/s41571-018-0004-4. Review. Erratum in: Nat Rev Clin Oncol. 2018 Apr 30;:.

PMID:
29666440
4.

Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men.

Waterhouse RL Jr, Van Neste L, Moses KA, Barnswell C, Silberstein JL, Jalkut M, Tutrone R, Sylora J, Anglade R, Murdock M, Shiffman Z, Vandenberg T, Shah N, Carter M, Krispin M, Groskopf J, Van Criekinge W.

Urology. 2019 Jun;128:62-65. doi: 10.1016/j.urology.2018.04.001. Epub 2018 Apr 13.

5.

Epigenetic risk score improves prostate cancer risk assessment.

Van Neste L, Groskopf J, Grizzle WE, Adams GW, DeGuenther MS, Kolettis PN, Bryant JE, Kearney GP, Kearney MC, Van Criekinge W, Gaston SM.

Prostate. 2017 Sep;77(12):1259-1264. doi: 10.1002/pros.23385. Epub 2017 Aug 1.

PMID:
28762545
6.

Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.

Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L, Grutters JPC, Sedelaar JPM, van Oort IM.

BJU Int. 2017 Nov;120(5):659-665. doi: 10.1111/bju.13861. Epub 2017 Apr 29.

7.

CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS.

Partin AW, VAN Criekinge W, Trock BJ, Epstein JI, VAN Neste L.

Trans Am Clin Climatol Assoc. 2016;127:313-327.

8.

A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients.

van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, Baldewijns MMLL, Schouten LJ, van den Brandt PA, Jeschke J, Yi JM, Schuebel KE, Ahuja N, Herman JG, Aarts MJ, Bosman FT, Van Criekinge W, van Engeland M.

Clin Cancer Res. 2017 Apr 15;23(8):2006-2018. doi: 10.1158/1078-0432.CCR-16-1236. Epub 2016 Oct 18.

9.

Promoter CpG island methylation in ion transport mechanisms and associated dietary intakes jointly influence the risk of clear-cell renal cell cancer.

Deckers IA, van Engeland M, van den Brandt PA, Van Neste L, Soetekouw PM, Aarts MJ, Baldewijns MM, Keszei AP, Schouten LJ.

Int J Epidemiol. 2017 Apr 1;46(2):622-631. doi: 10.1093/ije/dyw266.

PMID:
27789672
10.

Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.

Van Neste L, Partin AW, Stewart GD, Epstein JI, Harrison DJ, Van Criekinge W.

Prostate. 2016 Sep;76(12):1078-87. doi: 10.1002/pros.23191. Epub 2016 Apr 28.

11.

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA.

Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20.

PMID:
27108162
12.

Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria.

van Kessel KE, Van Neste L, Lurkin I, Zwarthoff EC, Van Criekinge W.

J Urol. 2016 Mar;195(3):601-7. doi: 10.1016/j.juro.2015.08.085. Epub 2015 Aug 29.

PMID:
26327355
13.

Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.

Deckers IA, Schouten LJ, Van Neste L, van Vlodrop IJ, Soetekouw PM, Baldewijns MM, Jeschke J, Ahuja N, Herman JG, van den Brandt PA, van Engeland M.

Clin Cancer Res. 2015 Aug 1;21(15):3492-500. doi: 10.1158/1078-0432.CCR-14-2049. Epub 2015 Apr 22.

14.

Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays.

de Ruijter TC, de Hoon JP, Slaats J, de Vries B, Janssen MJ, van Wezel T, Aarts MJ, van Engeland M, Tjan-Heijnen VC, Van Neste L, Veeck J.

Lab Invest. 2015 Jul;95(7):833-42. doi: 10.1038/labinvest.2015.53. Epub 2015 Apr 13.

15.

Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood.

Melotte V, Yi JM, Lentjes MH, Smits KM, Van Neste L, Niessen HE, Wouters KA, Louwagie J, Schuebel KE, Herman JG, Baylin SB, van Criekinge W, Meijer GA, Ahuja N, van Engeland M.

Cancer Prev Res (Phila). 2015 Feb;8(2):157-64. doi: 10.1158/1940-6207.CAPR-14-0198. Epub 2014 Dec 23.

16.

We are all individuals... bioinformatics in the personalized medicine era.

Van Neste L, Van Criekinge W.

Cell Oncol (Dordr). 2015 Feb;38(1):29-37. doi: 10.1007/s13402-014-0195-3. Epub 2014 Sep 10. Review.

PMID:
25204962
17.

Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.

Wojno KJ, Costa FJ, Cornell RJ, Small JD, Pasin E, Van Criekinge W, Bigley JW, Van Neste L.

Am Health Drug Benefits. 2014 May;7(3):129-34.

18.

CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.

Cleven AH, Derks S, Draht MX, Smits KM, Melotte V, Van Neste L, Tournier B, Jooste V, Chapusot C, Weijenberg MP, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2014 Jun 15;20(12):3261-71. doi: 10.1158/1078-0432.CCR-12-3734.

19.

Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.

Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI.

J Urol. 2014 Oct;192(4):1081-7. doi: 10.1016/j.juro.2014.04.013. Epub 2014 Apr 18.

20.

Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer.

Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, Glöckner SC, Tessema M, Van Neste L, Easwaran H, Schuebel KE, Licchesi J, Hooker CM, Ahuja N, Amano J, Belinsky SA, Baylin SB, Herman JG, Brock MV.

Clin Cancer Res. 2014 Apr 1;20(7):1856-64. doi: 10.1158/1078-0432.CCR-13-2109. Epub 2014 Jan 31.

21.

Genome-wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers.

Tessema M, Yingling CM, Liu Y, Tellez CS, Van Neste L, Baylin SS, Belinsky SA.

Carcinogenesis. 2014 Jun;35(6):1248-57. doi: 10.1093/carcin/bgt494. Epub 2014 Jan 7.

22.

Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population.

Brebi P, Maldonado L, Noordhuis MG, Ili C, Leal P, Garcia P, Brait M, Ribas J, Michailidi C, Perez J, Soudry E, Tapia O, Guzman P, Muñoz S, Van Neste L, Van Criekinge W, Irizarry R, Sidransky D, Roa JC, Guerrero-Preston R.

Epigenetics. 2014 Feb;9(2):308-17. doi: 10.4161/epi.27120. Epub 2013 Nov 15.

23.

Novel methylation biomarker panel for the early detection of pancreatic cancer.

Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, Keeley BP, Stark A, Herrera A, Wolfgang C, Pappou EP, Iacobuzio-Donahue CA, Goggins MG, Herman JG, Wang TH, Baylin SB, Ahuja N.

Clin Cancer Res. 2013 Dec 1;19(23):6544-6555. doi: 10.1158/1078-0432.CCR-12-3224. Epub 2013 Oct 2.

24.

An exploration of pathways involved in lung carcinoid progression using gene expression profiling.

Swarts DR, Van Neste L, Henfling ME, Eijkenboom I, Eijk PP, van Velthuysen ML, Vink A, Volante M, Ylstra B, Van Criekinge W, van Engeland M, Ramaekers FC, Speel EJ.

Carcinogenesis. 2013 Dec;34(12):2726-37. doi: 10.1093/carcin/bgt271. Epub 2013 Aug 8.

25.

Frequent inactivation of cysteine dioxygenase type 1 contributes to survival of breast cancer cells and resistance to anthracyclines.

Jeschke J, O'Hagan HM, Zhang W, Vatapalli R, Calmon MF, Danilova L, Nelkenbrecher C, Van Neste L, Bijsmans IT, Van Engeland M, Gabrielson E, Schuebel KE, Winterpacht A, Baylin SB, Herman JG, Ahuja N.

Clin Cancer Res. 2013 Jun 15;19(12):3201-11. doi: 10.1158/1078-0432.CCR-12-3751. Epub 2013 Apr 29.

26.

CD44 and OTP are strong prognostic markers for pulmonary carcinoids.

Swarts DR, Henfling ME, Van Neste L, van Suylen RJ, Dingemans AM, Dinjens WN, Haesevoets A, Rudelius M, Thunnissen E, Volante M, Van Criekinge W, van Engeland M, Ramaekers FC, Speel EJ.

Clin Cancer Res. 2013 Apr 15;19(8):2197-207. doi: 10.1158/1078-0432.CCR-12-3078. Epub 2013 Feb 26.

27.

Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.

Stewart GD, Van Neste L, Delvenne P, Delrée P, Delga A, McNeill SA, O'Donnell M, Clark J, Van Criekinge W, Bigley J, Harrison DJ.

J Urol. 2013 Mar;189(3):1110-6. doi: 10.1016/j.juro.2012.08.219. Epub 2012 Oct 8.

PMID:
22999998
28.

A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection.

Van Neste L, Bigley J, Toll A, Otto G, Clark J, Delrée P, Van Criekinge W, Epstein JI.

BMC Urol. 2012 Jun 6;12:16. doi: 10.1186/1471-2490-12-16.

29.

Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen.

Jeschke J, Van Neste L, Glöckner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, Baylin SB, Herman JG, Ahuja N.

Epigenetics. 2012 Jul;7(7):701-9. doi: 10.4161/epi.20445. Epub 2012 Jul 1.

PMID:
22647880
30.

Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA.

Cancer Cell. 2012 Mar 20;21(3):430-46. doi: 10.1016/j.ccr.2011.12.029.

31.

A DNA hypermethylation module for the stem/progenitor cell signature of cancer.

Easwaran H, Johnstone SE, Van Neste L, Ohm J, Mosbruger T, Wang Q, Aryee MJ, Joyce P, Ahuja N, Weisenberger D, Collisson E, Zhu J, Yegnasubramanian S, Matsui W, Baylin SB.

Genome Res. 2012 May;22(5):837-49. doi: 10.1101/gr.131169.111. Epub 2012 Mar 5.

32.

DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes.

Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste L, Baylin SB.

Nucleic Acids Res. 2012 May;40(10):4334-46. doi: 10.1093/nar/gks031. Epub 2012 Jan 25.

33.

The epigenetic promise for prostate cancer diagnosis.

Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W.

Prostate. 2012 Aug 1;72(11):1248-61. doi: 10.1002/pros.22459. Epub 2011 Dec 7. Review.

PMID:
22161815
34.

Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands.

O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, Clements EG, Cai Y, Van Neste L, Easwaran H, Casero RA, Sears CL, Baylin SB.

Cancer Cell. 2011 Nov 15;20(5):606-19. doi: 10.1016/j.ccr.2011.09.012.

35.

Epigenetic-based companion diagnostics.

Van Neste L, Jones GR, Van Criekinge W, Clark JS.

Per Med. 2011 Nov;8(6):623-631. doi: 10.2217/pme.11.70.

PMID:
29776209
36.

Genomic and epigenomic integration identifies a prognostic signature in colon cancer.

Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glöckner SC, de Freitas Calmon M, Hooker CM, Funes JM, Boshoff C, Smits KM, van Engeland M, Weijenberg MP, Iacobuzio-Donahue CA, Herman JG, Schuebel KE, Baylin SB, Ahuja N.

Clin Cancer Res. 2011 Mar 15;17(6):1535-45. doi: 10.1158/1078-0432.CCR-10-2509. Epub 2011 Jan 28.

37.

Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract.

Dhir M, Yachida S, Van Neste L, Glöckner SC, Jeschke J, Pappou EP, Montgomery EA, Herman JG, Baylin SB, Iacobuzio-Donahue C, Ahuja N.

Int J Cancer. 2011 Oct 15;129(8):1889-98. doi: 10.1002/ijc.25847. Epub 2011 Mar 11.

38.

Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells.

Ohm JE, Mali P, Van Neste L, Berman DM, Liang L, Pandiyan K, Briggs KJ, Zhang W, Argani P, Simons B, Yu W, Matsui W, Van Criekinge W, Rassool FV, Zambidis E, Schuebel KE, Cope L, Yen J, Mohammad HP, Cheng L, Baylin SB.

Cancer Res. 2010 Oct 1;70(19):7662-73. doi: 10.1158/0008-5472.CAN-10-1361. Epub 2010 Sep 14.

39.

Array-based DNA methylation profiling for breast cancer subtype discrimination.

Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, Pauwels P, Vermeulen PB, Dirix LY, Van Laere SJ.

PLoS One. 2010 Sep 7;5(9):e12616. doi: 10.1371/journal.pone.0012616.

40.

Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus.

Easwaran HP, Van Neste L, Cope L, Sen S, Mohammad HP, Pageau GJ, Lawrence JB, Herman JG, Schuebel KE, Baylin SB.

Cancer Res. 2010 Oct 15;70(20):8015-24. doi: 10.1158/0008-5472.CAN-10-0765. Epub 2010 Aug 24.

41.

Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc.

Licchesi JD, Van Neste L, Tiwari VK, Cope L, Lin X, Baylin SB, Herman JG.

Oncogene. 2010 Nov 4;29(44):5923-34. doi: 10.1038/onc.2010.322. Epub 2010 Aug 9.

42.

Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis.

Tessema M, Klinge DM, Yingling CM, Do K, Van Neste L, Belinsky SA.

Oncogene. 2010 Sep 16;29(37):5159-70. doi: 10.1038/onc.2010.255. Epub 2010 Jun 21.

43.

Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.

van Vlodrop IJ, Baldewijns MM, Smits KM, Schouten LJ, van Neste L, van Criekinge W, van Poppel H, Lerut E, Schuebel KE, Ahuja N, Herman JG, de Bruïne AP, van Engeland M.

Am J Pathol. 2010 Feb;176(2):575-84. doi: 10.2353/ajpath.2010.090442. Epub 2009 Dec 30.

44.

High content image cytometry in the context of subnuclear organization.

De Vos WH, Van Neste L, Dieriks B, Joss GH, Van Oostveldt P.

Cytometry A. 2010 Jan;77(1):64-75. doi: 10.1002/cyto.a.20807.

45.

Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation.

Mohammad HP, Cai Y, McGarvey KM, Easwaran H, Van Neste L, Ohm JE, O'Hagan HM, Baylin SB.

Cancer Res. 2009 Aug 1;69(15):6322-30. doi: 10.1158/0008-5472.CAN-09-0065. Epub 2009 Jul 14.

46.

Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer.

Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne AP, Smits KM, Khalid-de Bakker CA, Jonkers DM, Stockbrügger RW, Meijer GA, Oort FA, Iacobuzio-Donahue C, Bierau K, Herman JG, Baylin SB, Van Engeland M, Schuebel KE, Ahuja N.

Cancer Res. 2009 Jun 1;69(11):4691-9. doi: 10.1158/0008-5472.CAN-08-0142. Epub 2009 May 12.

47.

Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells.

McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W, Schuebel KE, Baylin SB.

Cancer Res. 2008 Jul 15;68(14):5753-9. doi: 10.1158/0008-5472.CAN-08-0700.

48.

Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.

Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB.

PLoS Med. 2008 May 27;5(5):e114. doi: 10.1371/journal.pmed.0050114.

49.

Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer.

Zhang W, Glöckner SC, Guo M, Machida EO, Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins DN, Ahuja N, Baylin SB.

Cancer Res. 2008 Apr 15;68(8):2764-72. doi: 10.1158/0008-5472.CAN-07-6349. Erratum in: Cancer Res. 2008 Jul 15;68(14):6030.

50.

Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation.

Fouse SD, Shen Y, Pellegrini M, Cole S, Meissner A, Van Neste L, Jaenisch R, Fan G.

Cell Stem Cell. 2008 Feb 7;2(2):160-9. doi: 10.1016/j.stem.2007.12.011.

Supplemental Content

Loading ...
Support Center